Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
about
Alpha-foetoprotein and/or liver ultrasonography for screening of hepatocellular carcinoma in patients with chronic hepatitis BHepatocellular carcinoma: From clinical practice to evidence-based treatment protocolsMultimodal treatment of hepatocellular carcinoma on cirrhosis: an updateManagement of chronic hepatitis B: Canadian Association for the Study of the Liver consensus guidelinesRisk prediction of hepatitis B virus-related hepatocellular carcinoma in the era of antiviral therapySurveillance for hepatocellular carcinoma.Management of hepatocellular carcinoma: An updatePrediction models of hepatocellular carcinoma development in chronic hepatitis B patientsRisk prediction models for hepatocellular carcinoma in different populations.Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update.Domain Analysis of Integrated Data to Reduce Cost Associated with Liver Disease.Global gene expression profiling reveals SPINK1 as a potential hepatocellular carcinoma markerRisk calculators for hepatocellular carcinoma in patients affected with chronic hepatitis B in Asia.A Circulating MicroRNA Signature Capable of Assessing the Risk of Hepatocellular Carcinoma in Cirrhotic Patients.GABPA predicts prognosis and inhibits metastasis of hepatocellular carcinoma.Immune Tolerant Chronic Hepatitis B: The Unrecognized RisksABO blood type correlates with survival in hepatocellular carcinoma following hepatectomy.Chronic hepatitis B in 2014: great therapeutic progress, large diagnostic deficit.The impact of infection on population health: results of the Ontario burden of infectious diseases study.An evidence-based multidisciplinary approach to the management of hepatocellular carcinoma (HCC): the Alberta HCC algorithmPredictability of liver-related seromarkers for the risk of hepatocellular carcinoma in chronic hepatitis B patients.Update on the Risk of Hepatocellular Carcinoma in Chronic Hepatitis B Virus InfectionPersonalized treatment of hepatitis B.Molecular epidemiology of hepatitis B virus.Level of hepatitis B surface antigen might serve as a new marker to predict hepatocellular carcinoma recurrence following curative resection in patients with low viral load.Increased glyceraldehyde-3-phosphate dehydrogenase expression indicates higher survival rates in male patients with hepatitis B virus-accociated hepatocellular carcinoma and cirrhosisLiver cancer: Approaching a personalized care.Family history influences the early onset of hepatocellular carcinoma.Association of HBV DNA replication with antiviral treatment outcomes in the patients with early-stage HBV-related hepatocellular carcinoma undergoing curative resection.Hepatocellular carcinoma risk prediction model for the general population: the predictive power of transaminasesClinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog.Disorder-related risk factors for revision total hip arthroplasty after hip hemiarthroplasty in displaced femoral neck fracture patients: a nationwide population-based cohort studySYNJ2BP inhibits tumor growth and metastasis by activating DLL4 pathway in hepatocellular carcinoma.A predictive model for carcinogenesis in patients with chronic hepatitis B undergoing entecavir therapy and its validation.Clinical-guide risk prediction of hepatocellular carcinoma development in chronic hepatitis C patients after interferon-based therapy.Elevated liver fibrosis index FIB-4 is not reliable for HCC risk stratification in predominantly non-Asian CHB patients.Hepatocellular carcinoma: current trends in worldwide epidemiology, risk factors, diagnosis, and therapeuticsSuccessful resection of hepatocellular cancer not amenable to Milan criteria and durable complete remission induced by systemic polichemotherapy after development of metastases - should we think about revising the current treatment guidelines in selPredictive Value of Antiviral Effects in the Development of Hepatocellular Carcinoma in the General Korean Population with Chronic Hepatitis BHepatocellular carcinoma: A global view.
P2860
Q24200785-F10D816F-8432-4B67-A544-55D2CBA7C638Q26783881-F5570617-48C2-4533-8EB0-229783DD62A9Q26825172-C67DE830-CF8C-47B7-A6BA-9F60B3CCB2CAQ27000080-666E2DDB-2847-47A7-BD2F-ACA6197560F9Q27022899-69574D79-4161-4E13-9EB1-9E4E1E1A0567Q27690269-09A95E71-7C74-4EBA-A59E-E220296D2E04Q27860530-BF8CFC1F-F574-46A4-9041-C486DF397743Q28066959-E7245827-3779-45C8-94B5-46069AE31981Q30383460-03CB1470-67AF-4A6B-A60E-AF60407270F2Q30391932-6B490400-D58D-4E7A-8746-C29DD44838C4Q30986369-01B0A8FA-3DF4-4117-8727-4DFDF1E5D810Q31113966-C9717CA5-F8A4-44C3-A290-3F38AB175B7FQ33661164-D496EE09-AF63-4DF2-AD72-318E0A03FBF6Q33674511-CADBAD63-064D-4230-B17B-934EF1E86EBAQ33733761-187265D1-EC65-4AB7-808D-022AFD6E0985Q33753902-82A3FE00-690F-4ED5-9205-F7549B0F905FQ33861119-3502A422-F3CE-4032-B0BC-2AAECD9D7BDAQ34137291-82C90B22-F3AB-4FC7-BE49-434C61B74292Q34409799-A0DB76CF-296A-49BB-8C6B-6E3556AA0858Q34417009-EC90E277-99C6-4EFD-BC2F-024924863CEDQ34684406-003205DB-C76D-44B3-946E-7B152B60F10DQ34892826-B7046C27-1F9C-4999-9F3F-238256E0A6D9Q35231805-F3B4219A-EAD6-469E-8FB0-A8B72A7A2D6CQ35331524-7EBD0A37-E6E8-4445-A14A-48A95B0D5F48Q35402699-E795520C-9E54-4817-9AF8-F46A1ECCD45FQ35753997-8B605E87-C46E-4758-B043-8E822AA9C63CQ35903794-D8C98584-72A7-44D5-A1EB-30C7DE13AD70Q36016036-96BB6B6C-EFE1-4B39-9961-BDAE045A2F94Q36705411-CFF1FD1F-161C-4586-AF58-7B0A22968F92Q36954705-0438DB04-D3F8-4CD9-B72A-7F2BB4FD3D3DQ36973383-A0E1ACE8-3513-4530-BC86-77B8C6384527Q36980864-55BC439F-2ED8-479B-8A73-BD306BCCA85EQ37113106-1A68C4FE-F713-44BC-86F7-F3CF453B6A64Q37257069-A2DC2B06-BA22-47DB-92A8-93CD121723C5Q37279232-61C8CA3F-0B63-46BC-9BD1-DA12DAF2E316Q37300543-673249DB-AE5C-42AA-892E-4C3E241E1FEBQ37355835-2D613418-4D67-4190-9757-A6657DDBFA82Q37376515-A75A0B82-CA3A-47F0-B6DE-6E16F6278750Q37381790-BF939471-6532-46F4-A1F1-24E8609408A8Q37589349-E245F580-99E7-4AEC-964F-49AB6E844B2B
P2860
Nomograms for risk of hepatocellular carcinoma in patients with chronic hepatitis B virus infection.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Nomograms for risk of hepatoce ...... c hepatitis B virus infection.
@en
Nomograms for risk of hepatoce ...... c hepatitis B virus infection.
@nl
type
label
Nomograms for risk of hepatoce ...... c hepatitis B virus infection.
@en
Nomograms for risk of hepatoce ...... c hepatitis B virus infection.
@nl
prefLabel
Nomograms for risk of hepatoce ...... c hepatitis B virus infection.
@en
Nomograms for risk of hepatoce ...... c hepatitis B virus infection.
@nl
P2093
P356
P1476
Nomograms for risk of hepatoce ...... c hepatitis B virus infection.
@en
P2093
Chien-Jen Chen
Hwai-I Yang
Morris Sherman
Uchenna H Iloeje
P304
P356
10.1200/JCO.2009.27.4456
P407
P577
2010-04-05T00:00:00Z